American Society of Hematology awards third round of Bridge Grants

March 24, 2014

(WASHINGTON, March 24, 2014)-- The American Society of Hematology (ASH), the world's largest professional society concerned with the causes and treatment of blood disorders, today announced the names of 15 research investigators who will receive critical interim support from the Society for hematology research proposals that, despite earning high scores, could not be funded by the National Institutes of Health (NIH) amid severe funding reductions. The support will come in the form of one-year, $100,000 ASH Bridge Grants, awards intended to help bridge these talented ASH member investigators to their next NIH research grant by funding efforts to gather additional data to strengthen the resubmission of their applications.

The 15 noteworthy ASH Bridge Grant recipients announced today join 29 hematologists that have been granted funding since ASH committed $9 million in Society funds to create the program in July 2012. Among these 29 talented investigators, nearly one-third have already successfully obtained NIH funding.

These statistics, coupled with current budget uncertainty for NIH, demonstrate a clear need for such bridge funding programs. Following a decade of flat funding for the agency, in 2013 the NIH budget was slashed by more than 5 percent as part of mandated across-the-board federal spending cuts known as sequestration. While Congress restored nearly $1 billion to the NIH budget for fiscal year 2014, a welcome boost that will allow for the creation of an estimated 385 research grants, funding for U.S. biomedical research remains insufficient to address the dire need for treatments and cures for some of the most deadly blood diseases worldwide. The current federal appropriation to NIH is more than $700 million short of the agency's pre-sequestration budget, leading an alarming number of both new and more experienced hematology researchers to consider abandoning their careers, leaving precious scientific innovation at a standstill.

"Despite small signs of improvement, the current NIH funding climate is far from perfect and the impact on biomedical innovation has been devastating," said ASH President Linda J. Burns, MD, of the University of Minnesota. "While our early success rates suggest that the ASH Bridge Grant program is making an impact, it is still a temporary fix for a larger problem. Lawmakers must understand the damaging effect that unpredictable funding will have on research and patients and invest in biomedical research."

The studies supported by ASH's third round of bridge grants span the breadth of hematology. Funded projects range from exploration of new therapeutic targets for multiple myeloma and osteolytic bone disease, to the causes and cures of anemias and iron overload disorders and the connection between autoimmunity and cancer. Other funded studies include one that evaluates drug regimens for leukemias and lymphomas based on genetic factors and another that aims to refine prognostic tools for chronic lymphocytic leukemia.

The 15 ASH Bridge Grants announced today constitute the first of two rounds of grants to be awarded this year. Beyond the Society's financial commitment that will provide for approximately 30 grants to be awarded annually through 2015, additional awards will be supplemented by support from corporate and individual contributors. Generous support from individual donors as well as Amgen, Inc.; the Atlanta Convention & Visitors Bureau; Genentech USA, Inc.; GlaxoSmithKline; Millennium: The Takeda Oncology Company; Novartis Pharmaceuticals, Inc.; and Onyx Pharmaceuticals, Inc. enabled the Society to award several additional bridge grants as part of this third round.

"As biomedical researchers across specialties find that they cannot depend solely on NIH funding, we predict that alternative funding opportunities like the ASH Bridge Grants will be increasingly valuable to the progress of U.S. biomedical innovation and will help retain talented hematologists in the field during times of financial hardship," said Dr. Burns.

Visit http://www.hematology.org/bridgegrantrecipients to view the complete list of third-round ASH Bridge Grant recipients.
-end-
To learn more about ASH's Bridge Grant Program, visit http://www.hematology.org/bridgegrants.

To make a donation, or take action in support of federal funding for biomedical research, visit http://www.hematology.org/fightnow.

The American Society of Hematology) is the world's largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology. The official journal of ASH is Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online.

American Society of Hematology

Related Hematology Articles from Brightsurf:

Study finds gender disparities in hematology research success
Hematologists who complete a mentored training program experience greater levels of academic success than those who do not; however, a study published today in Blood Advances suggests a slight discrepancy in success levels between male and female hematologists.

Survey suggests mentorship in medical school is vital to future of hematology
A survey of US hematology-oncology fellows suggests medical school plays an important role in shaping their interest in pursuing careers in hematology, particularly when students are exposed to hematology and oncology as part of core clerkships in internal medicine and pediatrics.

JAK inhibitors associated with aggressive lymphoma
Austrian researchers have discovered that a small number of patients taking targeted drugs known as Janus kinase (JAK) inhibitors to treat myelofibrosis may develop aggressive lymphomas.

For young adults with blood cancer, pediatric centers may improve survival
Adolescents and young adults with acute leukemia have a survival advantage if they receive treatment at a pediatric cancer center versus an adult center, according to a new study.

Global hematology diagnostics market estimated to expand at a robust CAGR over 2021
Hematology includes various IVD technologies such as blood analysis, flow cytometry, immunodiagnostics, molecular diagnostics, hemostasis, histology, and cytology.

Late-breaking hematology abstracts signal new, near-term therapeutic options for patients
In four clinical trials being presented today during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, researchers report promising results suggesting patients with blood disorders and several types of cancer will soon have significantly expanded options for treatment.

American Society of Hematology announces top trainee abstracts of 2016 ASH Annual Meeting
The American Society of Hematology (ASH) is pleased to recognize the following trainees with the highest-scoring abstracts in the categories of undergraduate student, medical student, graduate student, resident physician, and postdoctoral fellow at the 58th ASH Annual Meeting Dec.

ASH to expand family of blood journals with launch of new cutting-edge publication
The American Society of Hematology (ASH) will launch an open-access journal to complement Blood, its flagship publication and the most-cited journal in hematology.

Study finds common genetic variants that double risk for blood clots in African Americans
New research published online today in Blood the Journal of the American Society of Hematology, identifies common genetic variants predominantly found in African Americans that double their risk for blood clots.

Mount Sinai researchers present results at American Society of Hematology Meeting
Icahn School of Medicine at Mount Sinai researchers will present several landmark studies at the 2015 American Society of Hematology meeting Dec.

Read More: Hematology News and Hematology Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.